Medical company LaunchPad Medical Inc reported on Tuesday the receipt of the follow-on grant of up to USD1.8m from the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center and funded by the National Institute of Dental and Cranial Research to improve the translation of promising tissue engineering and regenerative medicine technologies for dental, oral and craniofacial clinical practice.
This grant, which follows the two prior grants from the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center, will allow the company to conduct a pivotal animal study as well as generate all the other required data to file an Investigational Device Exemption (IDE) application with the US FDA to start a clinical trial.
Approximately 30% of dental bone grafting cases existing graft materials fail to achieve the desired clinical results increasing the overall time and cost of these procedures. These patients must undergo a ridge augmentation procedure in which particulate-based bone graft materials are placed using membranes and fixation aids to contain the graft during the healing process.
The market research conducted in conjunction with Avenues, a marketing company involved with the resource center, confirmed the clinical need for an improved bone graft solution, concluded the company.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study